An exploratory analysis additionally showed that patients with PREDICT AR–positive tumors had better median overall survival as well (not reached vs. 32.1 weeks), although data for this outcome are still not mature.
“This hormonal agent reflected a safety profile very much like what has been seen in prostate cancer,” she reported, with fatigue, nausea, and decreased appetite predominating. The overall rate of grade 3 or worse adverse events related to the drug was 10%. “There were no new safety signals found, and this was a well-tolerated regimen,” she added.
Dr. Traina disclosed that she receives honoraria from Celgene, Eisai, and Genentech; has a consulting or advisory role with AstraZeneca, Eisai, Genentech, Genentech/Roche, Halozyme, Medivation, Mundipharma, and Pfizer; and receives research funding from AstraZeneca, Eisai, Genentech, Janssen, Medivation, Novartis, and Ziopharm Oncology.